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PERP, an apoptosis-associated target
of p53, is a novel member
of the PMP-22/gas3 family
Laura D. Attardi,1 Elizabeth E. Reczek,1 Corinna Cosmas,1 Elizabeth G. Demicco,1
Mila E. McCurrach,2 Scott W. Lowe,2 and Tyler Jacks1,3,4
1Department of Biology and Center for Cancer Research, and 3Howard Hughes Medical Institute, Massachusetts Institute
of Technology, Cambridge, Massachusetts 02139 USA; 2Cold Spring Harbor Laboratory, Cold Spring Harbor,
New York 11724 USA
The p53 tumor suppressor activates either cell cycle arrest or apoptosis in response to cellular stress. Mouse
embryo fibroblasts (MEFs) provide a powerful primary cell system to study both p53-dependent pathways.
Specifically, in response to DNA damage, MEFs undergo p53-dependent G1 arrest, whereas MEFs expressing
the adenovirus E1A oncoprotein undergo p53-dependent apoptosis. As the p53-dependent apoptosis pathway is
not well understood, we sought to identify apoptosis-specific p53 target genes using a subtractive cloning
strategy. Here, we describe the characterization of a gene identified in this screen, PERP, which is expressed in
a p53-dependent manner and at high levels in apoptotic cells compared with G1-arrested cells. PERP induction
is linked to p53-dependent apoptosis, including in response to E2F-1-driven hyperproliferation. Furthermore,
analysis of the PERP promoter suggests that PERP is directly activated by p53. PERP shows sequence
similarity to the PMP-22/gas3 tetraspan membrane protein implicated in hereditary human neuropathies such
as Charcot–Marie–Tooth. Like PMP-22/gas3, PERP is a plasma membrane protein, and importantly, its
expression causes cell death in fibroblasts. Taken together, these data suggest that PERP is a novel effector of
p53-dependent apoptosis.
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The p53 tumor suppressor gene plays a crucial role in
protecting organisms from developing cancer (Levine
1997). p53 is mutated in over half of all human cancers,
reflecting a selective pressure to remove this negative
regulator of cell proliferation during the course of tu-
morigenesis (Levine 1997). p53 mutations are found in
tumors of a wide variety of cell types, suggesting that
p53 normally inhibits tumor formation in many tissues.
Moreover, individuals with Li–Fraumeni syndrome, who
are heterozygous for a mutant p53 allele, are highly
prone to developing a variety of different cancer types
(Malkin et al. 1990). In addition, mice carrying targeted
mutations in the p53 gene develop tumors at 100% fre-
quency within a few months of birth (for review, see
Attardi and Jacks 1999).
Mechanistically, the p53 protein acts as a cellular
stress sensor (Giaccia and Kastan 1999). In response to a
number of forms of stress, including hyperproliferation,
DNA damage, and hypoxia, p53 levels rise, causing the
cell to undergo one of two fates: arrest in the G1 phase of
the cell cycle or genetically programmed cell death,
known as apoptosis (Levine 1997). The G1 arrest is part
of a checkpoint response whereby cells that have sus-
tained DNA damage pause in G1 to allow for DNA repair
before progression through the cell cycle, thereby limit-
ing the propagation of potentially oncogenic mutations.
The p53-dependent apoptotic pathway is also induced by
DNA damage in certain cell types, as well as in cells
undergoing inappropriate proliferation. Importantly,
however, the mechanism by which p53 dictates the
choice between the G1 arrest and the apoptotic pathways
is presently not well understood.
Mouse embryo fibroblasts (MEFs) represent an ideal
cell system in which to study both the G1 arrest and
apoptotic activities of p53. When treated with DNA-
damaging agents, wild-type MEFs activate the cell cycle
checkpoint response by arresting in G1 (Kastan et al.
1992). This response is clearly p53 dependent as p53-null
MEFs fail to undergo G1 arrest upon DNA damage treat-
ment. In contrast, hyperproliferative MEFs, such as
those expressing the adenovirus E1A oncoprotein, re-
spond differently to DNA damage treatment. By mecha-
nisms that are not well understood, these growth-dereg-
ulated fibroblasts are reprogrammed to undergo p53-de-
pendent apoptosis (Debbas and White 1993; Lowe et al.
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1993). Similarly, expression of c-Myc or E2F-1 renders
cells susceptible to p53-dependent apoptosis, which is
greatly enhanced by exposure to stresses such as serum
starvation or DNA-damaging agent treatment (Hermek-
ing and Eick 1994; Qin et al. 1994; Wagner et al. 1994;
Wu and Levine 1994; Soengas et al. 1999).
These observations and data from in vivo systems sup-
port the concept that activation of apoptosis by p53 in
incipient tumor cells plays an important role in tumor
suppression. For example, E1A and ras-expressing p53−/−
MEFs transplanted into nude mice form rapid tumors
compared with E1A/ras–p53+/+ MEFs, as do E1A/ras-ex-
pressing MEFs lacking the apoptotic effector proteins
caspase 9 or Apaf-1 (Lowe et al. 1994; Soengas et al.
1999). These data indicate that defects in the p53-depen-
dent apoptotic pathway contribute to tumor develop-
ment. Another example comes from transgenic mice
that express SV40 large T antigen in the choroid plexus
epithelium and, consequently, rapidly develop brain tu-
mors (Symonds et al. 1994). If a mutant T-antigen pro-
tein incapable of binding and sequestering p53 is ex-
pressed, tumor development is slowed dramatically, be-
cause of the activation of p53-dependent apoptosis.
Additional support for the role of p53-induced apoptosis
in tumor suppression comes from the demonstration
that some human tumor-derived p53 mutants are defec-
tive only in inducing the apoptotic pathway but not in
activating the G1 arrest pathway (Ryan and Vousden
1998).
Although the mechanism by which p53 activates G1
arrest is well characterized and involves primarily tran-
scriptional activation of the cyclin-dependent kinase in-
hibitor p21 (El-Deiry et al. 1993; Brugarolas 1995; Deng
et al. 1995), p53-dependent apoptosis is not well under-
stood. A wealth of evidence indicates that p53 is a tran-
scriptional activator protein (Levine 1997). However,
both transcriptional activation-dependent and -indepen-
dent functions of p53 have been shown to be important
for its ability to induce apoptosis, possibly reflecting dis-
tinct mechanisms of p53 action in different cell types
(Caelles et al. 1994; Wagner et al. 1994; Haupt et al. 1995;
Sabbatini et al. 1995; Attardi et al. 1996; Yonish-Rouach
1996). Previously, by testing a collection of p53 mutants,
we established that transcriptional activation by p53 is
critical for the induction of both G1 arrest in MEFs and
apoptosis in E1A-expressing MEFs (Attardi et al. 1996).
However, the mode of activation of these pathways by
p53 could be distinguished by examination of p53 tran-
scriptional target gene requirements. In particular, al-
though p21 was critical for mediating the p53-activated
G1 arrest response to DNA damage, it was not required
for the apoptotic response in E1A MEFs. This finding
suggested that p53 acts via distinct mechanisms to acti-
vate the two pathways, possibly through the activation
of different sets of target genes.
Several previously identified p53 target genes have
been proposed to play a role in cell death. Bax, a pro-
apoptotic member of the Bcl-2 family, has p53 binding
sites in its promoter, and direct activation of its pro-
moter could constitute the link between p53 and the
apoptotic machinery (Miyashita and Reed 1995). How-
ever, the requirement for Bax in p53-dependent cell
death is, at best, partial. For example, in E1A MEFs or in
the T antigen-induced brain tumor mouse model, levels
of apoptosis are reduced in a bax null background, in
contrast to being totally eliminated in the absence of p53
(McCurrach et al. 1997; Yin et al. 1997). In addition, Bax
is fully dispensable for p53-dependent cell death of thy-
mocytes in response to g-irradiation, indicating that it
may be more relevant in some cellular contexts than
others (Knudson et al. 1995). Other potential apoptosis
target genes have been discovered, including KILLER/
DR5 and PIGs (p53 inducible genes), but it remains to be
seen whether they play a role in p53-dependent apoptosis
(Polyak et al. 1997; Wu et al. 1997). As Bax is the only
p53 target gene for which loss-of-function experiments
suggest a function in the p53 cell death pathway and as
it is only a partial role, it is likely that other p53 target
genes in this pathway remain to be identified.
To further dissect the p53-dependent apoptotic path-
way activated in incipient tumor cells, we sought to
identify p53 target genes specifically induced during
apoptosis. Toward this end, we performed a differential
screen in which G1-arrested MEF RNA populations were
subtracted from apoptotic E1A MEF RNA populations.
The rationale for this strategy was to select against genes
induced by p53 in nonapoptotic cells, allowing for the
isolation of genes specifically up-regulated by p53 during
apoptosis. Although subtractive hybridization strategies
have been used previously to identify p53-responsive
genes such as p21, they have generally failed to identify
genes clearly involved only in apoptosis and not in G1
arrest (El-Deiry et al. 1993; Okamoto and Beach 1994;
Buckbinder et al. 1995; Polyak et al. 1997). These ap-
proaches have typically entailed comparing gene expres-
sion profiles of cell lines lacking p53 with cell lines over-
expressing p53, without distinguishing between the G1
arrest and apoptotic responses. Another advantage of the
strategy used here is that it relies on the response of
endogenous cellular p53 to DNA damage and is per-
formed using primary cells, making it very physiological.
Using this novel subtractive cloning approach, we have
isolated a new p53 target gene, PERP, a candidate effec-
tor in the p53-dependent apoptotic pathway.
Results
PERP, a novel p53 target gene, is expressed
preferentially during p53-mediated apoptosis
In an effort to isolate genes up-regulated by p53 specifi-
cally during apoptosis, we undertook a subtractive hy-
bridization strategy in which G1-arrested cDNA popula-
tions were subtracted from apoptotic cDNA populations
(Fig. 1A). In our screen, the tester population, from
which the target genes were sought, was comprised of
cDNA from DNA damage-treated E1A–p53+/+ MEFs
(apoptotic cells), whereas the driver consisted of cDNA
from DNA damage-treated p53+/+ MEFs (G1-arrested
cells). In addition, DNA damage-treated E1A–p53−/−
PERP, a p53 apoptosis-associated target gene
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populations were included in the driver population to
remove messages induced by E1A in a p53-independent
manner. We chose to use the DNA-damaging agent
doxorubicin for this screen as it effectively induced p53-
dependent G1 arrest in MEFs and p53-dependent apopto-
sis in E1A MEFs at the same dose and with similar ki-
netics (L.D. Attardi and T. Jacks, in prep.). To prepare the
G1-arrested RNA population for the screen, wild-type
MEFs were arrested with 0.2 µg/ml doxorubicin. As
doxorubicin was shown previously to induce arrest re-
sponses in multiple phases of the cell cycle, some of
which are p53 independent (L.D. Attardi and T. Jacks, in
prep.), we obtained a G1-arrested population by first syn-
chronizing the cells. Wild-type MEFs were synchronized
in G0 by serum starvation, stimulated to re-enter the cell
cycle by the addition of serum, and shortly thereafter,
treated with 0.2 µg/ml doxorubicin for 12 hr. This time
point was chosen because we had previously shown it to
be a point of peak expression of known p53 target genes
(L.D. Attardi and T. Jacks, in prep.). That G1 arrest had
occurred was confirmed by FACS analysis, which
showed a G1 arrest in the wild-type but not in p53
−/−
MEFs (Fig. 1B). To prepare apoptotic RNA for the screen,
E1A–p53+/+ MEFs were treated with 0.2 µg/ml doxoru-
bicin for 17–18 hr, a time at which apoptosis had clearly
been initiated (Fig. 1C) and when p53 target gene expres-
sion was maximal (L.D. Attardi, in prep.). At this time
point, between 23% and 31% of the cells were undergo-
ing apoptosis (two independent experiments), as assessed
by both trypan blue exclusion, which measures loss of
membrane integrity, and DAPI staining, which allows
analysis of nuclear integrity. When E1A–p53−/− MEFs
were treated with 0.2 µg/ml doxorubicin for ~ 17–18 hr,
they failed to undergo apoptosis, as expected (Fig. 1C).
cDNA was made from poly(A)+ RNA derived from
each population, and the driver population was sub-
tracted from the tester population using a variant of rep-
resentational difference analysis (RDA), termed PCR-Se-
lect (Clontech; see Materials and Methods). Cloned
cDNAs were sequenced to determine their identities and
Figure 1. Subtractive hybridization strat-
egy. (A) Scheme for differential screen.
cDNA from G1-arrested MEFs (doxorubi-
cin-treated MEFs) and doxorubicin-treated
E1A–p53−/− MEFs was pooled and sub-
tracted from cDNA from apoptotic MEFs
(doxorubicin-treated E1A–p53+/+ MEFs).
(B) Doxorubicin induces a p53-dependent
G1 arrest. For the G1-arrested population
in the screen, wild-type MEFs were syn-
chronized by serum starvation, released
into the cell cycle, and then treated with
doxorubicin to induce G1 arrest. FACS
profiles of both wild-type and p53-null
MEFs are shown and include synchronized
cells, cells stimulated to re-enter the cell
cycle for 24 hr, and cells G1-arrested with
doxorubicin. (C) Doxorubicin induces a
p53-dependent apoptotic response in E1A
MEFs. Shown here are data from one ex-
periment of two performed to prepare
RNA for the subtraction experiment. The
percentage of viable E1A–p53+/+ and E1A–
p53−/− cells after doxorubicin treatment is
plotted as a function of time. Cell death
was measured both by trypan blue exclu-
sion, to measure loss of membrane integ-
rity, and DAPI staining, to examine
nuclear morphology, and the techniques
gave equivalent results.
Attardi et al.
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were validated by probing Northern blots to confirm
apoptosis-specific expression. Initially, cDNAs were
used to probe blots containing RNA from G1-arresting
cells (doxorubicin-treated wild-type MEFs), apoptotic
cells (doxorubicin-treated E1A–p53+/+ MEFs), and doxo-
rubicin-treated E1A–p53−/− MEFs. One clone was par-
ticularly notable because it was isolated multiple times
and because it showed a dramatic difference in levels
between apoptotic and G1-arrested populations. This
gene, PERP (p53 apoptosis effector related to PMP-22),
was expressed at high levels in apoptotic cells compared
with G1-arrested or doxorubicin-treated E1A–p53
−/−
cells (Fig. 2A) and thus represented a good candidate for
a downstream target of p53 in the apoptotic pathway.
PERP induction is linked specifically
to the p53-dependent apoptotic pathway
To characterize PERP more fully, we analyzed its expres-
sion in a variety of contexts. We first examined the ki-
netics of PERP expression during apoptosis by perform-
ing a time course analysis. p53+/+, E1A–p53+/+, and E1A–
p53−/− MEFs were treated with 0.2 µg/ml doxorubicin,
and cells were collected for RNA preparation at various
time points after the initiation of DNA damage treat-
ment (Fig. 2B). Northern blot analysis revealed some in-
duction of PERP during G1 arrest, but to very moderate
levels. Induction was more clearly observed upon doxo-
rubicin treatment in apoptotic E1A MEFs, with accumu-
lation of PERP message to high levels compared with the
G1-arresting population. High-level PERP expression
correlated with the induction of cell death, with 21% of
cells undergoing apoptosis by 16 hr. PERP was not ex-
pressed significantly in E1A–p53−/− MEFs, indicating
that both basal expression and induction of this gene by
DNA damage are p53 dependent. Accumulation of high
levels of PERP gene expression are thus dependent on
p53, E1A, and DNA damage, all of which are essential for
E1A-induced apoptosis in MEFs.
Sequential probing of the time course Northern blot
revealed that other p53 target gene mRNAs generally
accumulate to similar levels in G1-arresting and apop-
totic cells (Fig. 2B). Genes tested included p21, cyclin G,
mdm-2, IGF–BP-3, KILLER/DR5, and most interest-
ingly, the proapoptotic regulator bax (for review, see El-
Deiry 1998). As Bax is a Bcl-2 family member that is
sufficient to induce apoptosis in certain contexts, its ac-
tivation by p53 has been proposed to lead to apoptosis
(Oltvai et al. 1993). In addition, E1A–bax−/− MEFs are
partially compromised for apoptosis induced by DNA
damage (McCurrach et al. 1997). However, we find that
bax is induced to similar levels in arrested and apoptotic
cells (Fig. 2B,E), indicating that p53 activation of bax
transcription does not dictate the specific fate that MEFs
undergo. Curiously, IGF–BP-3, a p53 target gene pro-
posed to be involved in apoptosis by binding and neu-
tralizing the IGF-1 survival factor (Buckbinder et al.
1995), is expressed in arresting but not apoptotic cells
and is inhibited by DNA damage treatment. Moreover,
although it is not expressed in apoptotic E1A–p53+/+
MEFs, it is expressed in E1A–p53−/− MEFs. KILLER/DR5
is another p53 target gene that has been shown in some
systems to be sufficient to induce apoptosis (Wu et al.
1997). Here, we observed that the levels of KILLER/DR5
are similar in arresting and apoptotic cells. In contrast,
PERP represents a good candidate to specify the cell
death decision, as its levels in apoptotic and arresting
cells differ significantly. In addition, the induction ki-
netics of PERP in response to DNA damage and its p53
dependence are similar to those of other p53 target genes,
suggesting that PERP is a direct target of p53 (see below).
Also, as with other p53 target genes, basal levels of PERP
are higher in E1A MEFs than in wild-type MEFs, because
of stabilization of p53 in these cells (Lowe and Ruley
1993).
To determine whether PERP is a component specific
to the p53-activated apoptotic pathway or if it is gener-
ally induced during apoptosis, we examined the expres-
sion of PERP in other apoptotic contexts. To examine
the expression of PERP in another situation of p53-de-
pendent cell death, we examined wild-type MEFs treated
with UVC light, which undergo p53-dependent apoptosis
at early time points (A. de Vries and L.D. Attardi, un-
publ.). After 20 J/m2 of UVC treatment, PERP levels in-
creased in wild-type MEFs, concomitant with the induc-
tion of apoptosis (Fig. 2C). In contrast, PERP was not
induced in p53−/− cells, which also do not undergo apop-
tosis at these time points. Even as the p53−/− cells initi-
ated apoptosis, however, there was no obvious induction
of PERP (Fig. 2C, last lane). These data suggest that in-
duction of PERP is associated specifically with p53-de-
pendent apoptosis. Furthermore, as in the previous
analysis, the similar kinetics of induction of PERP and
the well-characterized p53 target gene mdm-2 by UVC
suggests that PERP is a direct target of p53.
The analysis of transformed p53-deficient MEFs con-
firmed the specificity of PERP induction for the p53
apoptotic pathway. E1A/ras-expressing-p53−/− MEFs,
when treated with TNFa, undergo p53-independent
apoptosis (Lanni et al. 1997). Upon induction of cell
death by 20 ng/ml TNFa treatment, there was no in-
crease in PERP RNA levels, despite the fact that cell
death had been induced (Fig. 2D). Moreover, the levels of
expression were much lower than those seen in apop-
totic E1A MEFs (Fig. 2D, lane 5). These data indicate that
PERP is not generally induced in all contexts of apopto-
sis in fibroblasts but, rather, that it is linked to the p53-
dependent apoptotic response.
To determine whether PERP activation is an early
event in the pathway thus far defined for p53-mediated
apoptosis, we examined PERP induction in cells blocked
in the apoptotic pathway by expression of Bcl-2. Bcl-2
has been shown previously to inhibit p53-induced apop-
tosis in MEFs (McCurrach et al. 1997), presumably by
blocking caspase 9 activation, a late event in the path-
way. E1A/ras-expressing cells, which, like E1A-express-
ing cells, are sensitive to p53-dependent apoptosis, were
tested for induction of PERP, either in the absence or
presence of Bcl-2 expression. As expected, in the absence
of p53, doxorubicin treatment did not induce PERP ex-
PERP, a p53 apoptosis-associated target gene
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Figure 2. PERP induction is correlated with activation of the p53-dependent apoptotic pathway. (A) Northern blot analysis shows a
1.9-kb message, PERP, that is up-regulated in apoptotic E1A MEFs (middle lane) compared with G1-arrested MEFs (left lane) and
E1A–p53−/− MEFs (right lane). The blot was reprobed with GAPDH as a loading control. (B) Time course analysis of PERP and p53
target gene message levels in MEFs undergoing G1 arrest, E1A MEFs undergoing apoptosis, and doxorubicin-treated E1A–p53
−/− MEFs.
PERP message accumulates to significantly higher levels in apoptotic cells than in G1-arrested cells. The blot was probed with GAPDH
as a loading control. (C) PERP is induced in another context of p53-dependent apoptosis. Northern blot analysis shows that PERP is
induced as wild-type MEFs undergo apoptosis in response to UV light. It is not induced in the p53−/− MEFs, which are not undergoing
apoptosis. The percentages of cells undergoing apoptosis are indicated (bottom). The blot was probed with GAPDH as a loading control.
(D) PERP is not induced during p53-independent apoptosis. Northern blot analysis shows RNA derived from TNF-a-treated E1A/ras–
p53−/− (transformed) fibroblasts. The percentages of cells undergoing apoptosis are indicated (bottom). For comparison, lane 5 includes
RNA from E1A MEFs undergoing apoptosis, in which PERP mRNA levels are much higher than in TNF-a-treated samples. The blot
was probed with GAPDH as a loading control. (E) PERP Induction is not inhibited by Bcl-2. Northern blot analysis shows that PERP
is still induced in response to doxorubicin in cells that express Bcl-2. Bax levels, in contrast, remain stable in response to doxorubicin.
The blot was probed with GAPDH as a loading control. The graph (bottom) shows the cell death profiles in cells of various genotypes,
with only p53+/+, non-Bcl-2-expressing cells undergoing apoptosis.
Attardi et al.
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pression, irrespective of bcl-2 status (Fig. 2E). In the pres-
ence of p53, and in the absence of Bcl-2, induction of
PERP was observed upon doxorubicin treatment, as seen
previously. Interestingly, in the presence of Bcl-2, which
successfully blocked apoptosis (see Fig. 2E), PERP was
still induced by doxorubicin. Bax, in contrast, was only
marginally induced under these conditions. These data
indicate that induction of PERP is upstream of the block
imposed by Bcl-2 and suggest that its activation is an
early event during apoptosis rather than a consequence
of cell death. Taken together, these findings support the
candidacy of PERP as a key mediator between p53 and
the apoptotic machinery.
The PERP promoter is p53 responsive
The p53-dependence and kinetics of PERP expression in
response to DNA damage resemble that of other well-
defined p53 target genes. To begin to establish whether
PERP is a direct transcriptional target of p53, we isolated
4 kb of PERP genomic sequences upstream of the puta-
tive transcriptional start site and tested them for respon-
siveness to p53. Upon visual inspection of this genomic
sequence, we found two putative p53 binding sites with
significant similarity to the p53 consensus binding site
(Fig. 3A). These sites are located at ~ 200 bp and ~ 2.1 kb
upstream of the proposed start site of transcription,
which we assigned based on primer extension analysis,
cDNA cloning, and EST analysis (data not shown). We
also noted additional potential p53 binding sites in the
first intron (data not shown). To examine the p53 respon-
siveness of the PERP promoter, we fused this upstream
region to a luciferase reporter construct to create pPERP-
luc1 and introduced it into MEFs (Fig. 3B). As a negative
control, we tested the pGL3Basic vector that serves as
the backbone for the PERP reporter construct. As a posi-
tive control for p53 responsiveness, we tested the PG13–
Luc vector that contains 13 multimerized p53 binding
sites (El-Deiry et al. 1993). Upon introduction of the
PERP reporter plasmid into wild-type MEFs, there was
slightly enhanced activity (2.5-fold) relative to the p53-
null MEFs. Upon cointroduction of the PERP reporter
and a p53 expression vector into p53-null MEFs, how-
ever, a dramatic increase in luciferase activity was ob-
served (29-fold relative to p53-null MEFs without exog-
enous p53), indicating that the promoter is p53 respon-
Figure 3. The PERP promoter is p53 re-
sponsive. (A) Schematic of the pPERPluc1
luciferase reporter containing the PERP
promoter region. The arrow represents the
putative start site of transcription. The po-
sition of two potential p53 binding sites (at
−2097 and −218) with significant homol-
ogy to the published consensus sequence
(18 out of 20 and 16 out of 20 matches,
respectively) are indicated by yellow dia-
monds and their sequences are shown.
Mismatches are indicated in red. (B) The
4-kb region containing the PERP promoter
is activated by p53. The pPERPluc1 re-
porter was transfected into p53−/− MEFs
(lavender bars), wild-type MEFs (fuchsia
bars), or p53−/− MEFs cotransfected with
human p53 (green bars). Values shown are
given relative to the pGL3Basic backbone
plasmid in p53−/− MEFs and represent the
average of three separate experiments. Re-
porters include pPERPluc1 (diagramed
above); pGL3Basic luciferase reporter with
no promoter/enhancer (Promega); PG13–
Luc1 (13 copies of a p53 binding site placed
upstream of the polyoma promoter and lu-
ciferase); and MG15–Luc (15 copies of a
mutant p53 binding site upstream of the
polyoma promoter and luciferase).
PERP, a p53 apoptosis-associated target gene
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sive. The pGL3Basic reporter showed a marginal change
in activity upon introduction of p53. The PG13–Luc
positive control, like the PERP reporter, displayed in-
creased activity in wild-type relative to p53-null MEFs
and even greater activity in p53-null MEFs upon intro-
duction of exogenous p53. This more marked response
seen with PG13–Luc than with pPERPluc1 presumably
reflects the larger number of p53 binding sites. The
MG15–Luc reporter containing mutant p53 sites did not
respond to endogenous or exogenous p53. These data
support the view that PERP is a direct target of p53,
involved in p53-dependent apoptosis.
PERP is induced during E2F-1 activation
of the p53-dependent cell death pathway
If PERP is an important player in the p53-dependent cell
death pathway, it would be predicted that proliferative
signals other than E1A that activate this pathway would
induce PERP expression. Thus, we tested whether PERP
could be induced by E2F-1, which also causes both inap-
propriate cell proliferation and p53-dependent cell death
(Qin et al. 1994; Wu and Levine 1994). Wild-type E2F-1
or a carboxy-terminal truncation mutant lacking the
transactivation domain (E2F-1DC) were transduced into
wild-type or p53−/− MEFs by retroviral infection. Forty-
eight hours after the infection, when wild-type cells ex-
pressing full-length E2F-1 were clearly undergoing apop-
tosis, PERP levels were induced (Fig. 4). This high-level
induction was not observed in the cells expressing the
transcriptionally compromised form of E2F-1 (E2F-1DC)
or in p53−/− cells expressing full-length E2F-1, indicating
that both transcriptionally active E2F-1 and p53 are re-
quired to up-regulate PERP expression to high levels. Ex-
amination of the previously characterized E2F-1 target
gene cyclin A (Hurford et al. 1997) shows comparable
induction in full-length E2F-1-infected wild-type and
p53−/− cells (whereas the transactivation mutant E2F-1
failed to induce cyclin A, as expected), indicating that
the absence of PERP induction in the p53-null cells was
not due to inefficient retroviral infection. Rather, these
data suggest a specific link between PERP induction and
E2F-1-induced apoptosis.
PERP encodes a new member of the PMP-22/gas3
family
The full-length PERP cDNA was cloned by RACE (see
Materials and Methods). The size of the isolated cDNA
matched the size of the mRNA detected by Northern
blot, suggesting that a complete cDNA was obtained.
Furthermore, the cloned cDNA matches several entries
in the EST database, which included cDNAs with 58
ends only a few nucleotides longer than the PERP cDNA
we isolated. Analysis of the cDNA revealed a 193-amino-
acid ORF, encoding a protein of predicted molecular
mass of 21 kD (Fig. 5A). Examination of the amino acid
sequence by Pfam and BLOCKS analysis identified a
similarity to PMP-22 (Fig. 5B), a member of an expanding
family of tetraspan membrane proteins associated with
growth regulation. This family also includes EMP-1 (ep-
ithelial membrane protein 1), EMP-2, EMP-3, and MP20
(lens membrane protein) (for review, see Naef and Suter
1999). Importantly, the PMP-22 gene is implicated in
several common human demyelinating peripheral neu-
ropathies, including Charcot–Marie–Tooth Type 1A
(CMT1A) and hereditary neuropathy with liability to
pressure palsies (HNPP), both characterized by Schwann
cell growth deregulation and myelin defects (Naef and
Suter 1999). Moreover, PMP-22 was cloned previously
and characterized as gas3 (growth arrest specific 3) a gene
up-regulated in response to serum starvation of NIH-3T3
cells (Schneider et al. 1988). Similar to PERP, the PMP-
22/gas3 message is ~ 1.8 kb, with a small open reading
frame (ORF; 160 amino acids) (Schneider et al. 1988;
Spreyer et al. 1991; Welcher et al. 1991). Additionally,
consistent with the sequence similarity of PERP to PMP-
22/gas3, the Kyte–Doolittle hydropathy profile predic-
tion for PERP indicates that it also has four membrane-
spanning regions (modeled in Fig. 5C). Significantly,
however, PMP-22/gas3 regulation is clearly distinct
from that of PERP, as demonstrated by analysis of its
expression during p53-mediated G1 arrest and apoptosis
in the MEF system (Fig. 5D). PMP-22/gas3 levels of ex-
pression were highest in the E1A–p53−/− cells, and levels
were higher in the G1-arresting population than in the
apoptotic population. Taken together, these data indi-
cate that PMP-22/gas3 and PERP, although potentially
functionally similar, are expressed in very different pat-
terns.
Figure 4. PERP is up-regulated during E2F-1-induced cell
death. Wild-type and p53-null MEFs were infected with retro-
viruses carrying either a full-length or a mutant form of E2F-1
lacking the transactivation domain (E2F-1DC, comprising resi-
dues 1–409 of E2F-1). Forty-eight hours after infection, PERP
expression was observed only in the wild-type cells infected
with full-length E2F-1, correlating with a visible induction of
apoptosis. The E2F-1 target gene cyclin A, in contrast, is in-
duced in full-length E2F-1-infected wild-type and p53−/− MEFs,
relative to background endogenous cyclin A levels (seen in E2F-
1DC-infected cells). The blot was probed with GAPDH as a
loading control.
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In addition, human EST homologs of mouse PERP
were present in the database. According to the Sanger
Centre human genome project, PERP has been assigned
to human chromosome 6q24. This region is mutated in a
variety of cancers, including melanoma, cervical cancer,
ovarian cancer, and breast cancer (Millikin et al. 1991;
Foulkes et al. 1993; Noviello et al. 1996; Mazurenko et
al. 1999), raising the possibility that PERP might be the
target of mutation during human tumorigenesis.
PERP localizes to the plasma membrane
The similarity of PERP protein to the PMP-22/gas3 pro-
tein family and its hydropathy profile suggested that it is
a membrane protein. PMP-22/gas3 is present in the ER,
Golgi, and on the plasma membrane (for review, see Naef
and Suter 1999). To determine the subcellular localiza-
tion of PERP, a carboxy terminally HA-tagged variant
was expressed in NIH-3T3 or E1A–p53−/− cells. Upon
Figure 5. PERP is a new member of the PMP-22/gas3 family. (A) cDNA and amino acid sequence of PERP. (B) Alignment of PERP
and PMP-22/gas3 from several species (human, mouse, rat) is shown. Identical amino acids are highlighted in red, and similar amino
acids are highlighted in yellow. (C) Molecular model of PERP in the plasma membrane, as determined by transmembrane prediction
programs. (D) Northern blot analysis shows that PMP-22/gas3 is expressed in a pattern distinct from PERP during p53-dependent G1
arrest in MEFs and apoptosis in E1A MEFs. The blot was probed with GAPDH as a loading control.
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immunostaining with anti-HA antibodies, PERP protein
was observed in discrete cytoplasmic vesicular struc-
tures and on the plasma membrane (Fig. 6A,C,E). Double
immunofluorescence analysis was performed to identify
the subcellular structures showing PERP staining. Cos-
taining with MitoTracker to detect mitochondria
showed some potential overlap, but many distinct re-
gions as well, suggesting that PERP is not exclusively
localized to mitochondria (Fig. 6A,B). Costaining with an
antibody directed against b-COP (a Golgi apparatus
marker), however, revealed colocalization of PERP and
the Golgi apparatus (Fig. 6C–F). This pattern of localiza-
tion to the secretory pathway and the plasma membrane
is reminiscent of that of PMP-22/gas3, supporting the
idea that PERP is a bona fide member of the PMP-22/
gas3 family. The localization of PERP to the Golgi appa-
ratus is likely to reflect protein passing through the
secretory pathway en route to the plasma membrane,
although it remains possible that PERP has an intracel-
lular function as well.
PERP is sufficient to induce cell death
To determine whether PERP might be a downstream me-
diator of p53-dependent apoptosis, capable of substitut-
ing for p53 itself, PERP was introduced into E1A–p53−/−
cells. We have shown previously that reintroduction of
p53 into these cells resensitizes them to undergo apop-
tosis (Attardi et al. 1996). E1A–p53−/− cells were trans-
fected with PERP, with p53 as a positive control, or with
b-galactosidase as a negative control. After 48 hr, cells
were fixed, immunostained for each expressed protein,
and examined morphologically. Many cells expressing
either p53 or PERP showed characteristic cell rounding
and cytoplasmic shrinkage, with blebbing nuclei, typical
of apoptotic cells (Fig. 7A). Control cells expressing b-ga-
lactosidase, in contrast, exhibited only background lev-
els of cell death. Levels of PERP-induced cell death were
intermediate between the background levels and those
induced by p53 (Fig. 7B). The difference in potency be-
tween p53 and PERP in this assay could be explained by
PERP being only one of two or more components of the
p53-mediated cell death pathway and, thus, only par-
tially reconstituting the p53 response. Alternatively, this
difference could reflect the increased sensitivity of the
HA antibody (relative to the p53 antiserum) in detecting
low level-expressing cells, which are not as prone to un-
dergo apoptosis. Although such an overexpression assay
cannot definitively prove that inducing cell death is an
important physiological function of PERP, it is consis-
tent with PERP acting as a p53 cell death target gene.
To characterize the nature of PERP-induced cell death
more fully, we determined the effect of PERP expression
in the presence of the general apoptosis inhibitor Bcl-2.
Coexpression of Bcl-2 with either p53 or PERP resulted
in an inhibition of cell death (Fig. 7C), suggesting that
the cell death induced by PERP occurs via apoptosis.
Furthermore, these data are consistent with PERP func-
tioning through the same pathway as p53 (McCurrach et
al. 1997) and acting as an important mediator of p53-
induced apoptosis.
Discussion
Activation of a cellular suicide program is a key mecha-
nism by which p53 acts as a tumor suppressor. Hyper-
proliferative signals, such as those sensed by incipient
tumor cells, activate p53, resulting in the induction of
the cell death pathway. Mouse or cell culture model sys-
tems in which cells express the oncoproteins E1A, SV40
large T antigen, c-Myc, or E2F-1 show increased p53 lev-
els and a consequent propensity to undergo apoptosis
(Lowe et al. 1993; Lowe and Ruley 1993; Hermeking and
Eick 1994; Qin et al. 1994; Symonds et al. 1994; Wagner
et al. 1994; Wu and Levine 1994). Although the events
downstream of p53 in this process have been obscure,
recently the steps leading to p53 activation have begun
Figure 6. PERP localizes to the Golgi apparatus and the plasma
membrane. (A,B) Fibroblasts were transfected with PERP–HA
and immunostained with anti-HA antibodies (A) and Mito-
Tracker (B). Many regions of staining are nonoverlapping, sug-
gesting that PERP is not exclusively localized to the mitochon-
dria. (C–F) E1A–p53−/− MEFs were transfected with PERP–HA
and immunostained with anti-HA (C,E) and anti-b-COP (D,F).
Regions of vesicular HA staining coincide with b-COP staining,
suggesting that PERP is localizing to the Golgi apparatus (ar-
rows). In addition, some cells show plasma membrane staining,
seen as uniform cell staining (E).
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to be elucidated. In response to expression of the E1A or
c-Myc oncoproteins, induction of the tumor suppressor
protein p19ARF and its effects on the Mdm-2 protein
cause p53 to be stabilized (Bates et al. 1998; de Stanchina
et al. 1998; Sherr 1998; Zindy et al. 1998). The fact that
p19ARF is mutated in a large percentage of human tu-
mors (Sherr 1998) further supports the notion that onco-
gene-induced stabilization of p53 via p19ARF and the sub-
sequent activation of cell death by p53 are important for
p53 tumor suppressor function. In terms of more down-
stream steps in the oncogene-activated p53 cell death
pathway, well-characterized components of the apop-
totic machinery, Apaf-1 and caspase-9, as well as the
release of cytochrome c from the mitochondria have
been shown to be involved (Fearnhead et al. 1998; Juin et
al. 1999; Soengas et al. 1999). However, what lies be-
tween p53 and the proteolytic events stimulated by the
Apaf-1/caspase-9/cytochrome c apoptosome is un-
known. One potential component is the p53 target gene
bax, a proapoptotic member of the Bcl-2 family. The fact
that E1A–bax−/− cells are partially defective for apopto-
sis implicates Bax as a critical component of the apop-
tosis pathway in this system (McCurrach et al. 1997).
However, from our experiments it is clear that transcrip-
tional activation of bax by p53 is not an obvious deter-
minant of apoptosis, as it accumulates to similar levels
during the activation of G1 arrest and apoptosis. This
finding is supported by previous studies showing that a
mutant form of p53, p53DPP1, is capable of inducing Bax
normally but is defective in activating apoptosis (Saka-
muro et al. 1997). Thus, Bax may act as a rheostat, help-
ing to set the threshold levels of signals to induce apop-
tosis but not specifying the cell death fate directly.
The mechanism by which p53 impinges on the apop-
tosis machinery has thus remained largely elusive. Gen-
erally speaking, both transcriptional activation-depen-
dent and -independent activities of p53 have been pro-
posed to play a role in this process (Caelles et al. 1994;
Wagner et al. 1994; Haupt et al. 1995; Sabbatini et al.
1995; Attardi et al. 1996; Yonish-Rouach 1996). For ex-
ample, transcriptional repression of genes by p53 has
been implicated in apoptosis in some systems (Murphy
et al. 1996). In this E1A MEF system, however, we
showed previously that transcriptional activation by p53
is crucial for its ability to induce cell death and, further-
more, that no other activities of the protein were obvi-
ously required (Attardi et al. 1996). As a result, we
sought to identify genes activated by p53 and responsible
for mediating apoptosis in this setting, as a model for
understanding the cell death that occurs in newly form-
ing tumor cells in vivo.
A number of target genes activated by p53 have been
described previously, including p21, mdm-2, bax,
GADD45, cyclin G, KILLER/DR5, IGF–BP-3, Fas, and
PIG3 (for review, see El-Deiry 1998). The roles of these
diverse genes in mediating p53 function are understood
to variable extents. For example, p21 is a cyclin-depen-
dent kinase inhibitor known to be essential for mediat-
ing the G1 arrest checkpoint function of p53 (Brugarolas
1995; Deng 1995). Mdm-2, which binds p53 and conse-
quently causes it to be degraded by the proteasome, is
involved in negative feedback regulation of p53 (for re-
view, see Sherr 1998). Several p53 target genes such as
bax, KILLER/DR5, Fas, and PIG3 have been proposed to
play roles in apoptosis (El-Deiry 1998). As mentioned
previously, Bax is clearly important in some contexts of
p53-dependent cell death but not others. KILLER/DR5, a
death domain-containing receptor for the TRAIL (TNF-
related apoptosis inducing ligand) ligand, is also induced
by p53, and its expression is sufficient to induce cell
death (Wu et al. 1997), but its requirement for p53-de-
pendent cell death is unknown. In addition, transcrip-
tional activation of Fas, another death-domain contain-
ing protein, by p53 has been documented (Owen-Scaub
et al. 1995), although there is also evidence indicating
Figure 7. PERP is sufficient to induce cell death. (A) Expres-
sion of PERP induces apoptotic morphology. Cells transfected
with PERP–HA and immunostained with anti-HA and DAPI
show apoptotic morphology (shrunken cell bodies and blebbing
nuclei) when examined by immunofluorescence. (B) Expression
of PERP induces cell death. PERP induces cell death in E1A–
p53−/− MEFs at a level intermediate between p53 and the back-
ground level of the negative control (b-galactosidase). Data rep-
resent the average of four experiments. (C) Bcl-2 expression in-
hibits PERP-induced cell death. Coexpression of Bcl-2 lowers
the percentage of cells undergoing apoptosis in both p53- and
PERP-expressing samples. Data represent the average of three
experiments.
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that Fas is dispensable for p53-mediated apoptosis
(O’Connor and Strasser 1999). Finally, the PIGs, which
are collectively induced upon overexpression of p53 in a
colon cancer cell line, encode proteins that are generally
connected to the redox state of the cell. This has led to
the hypothesis that p53 acts by affecting the production
of reactive oxygen species (ROS), leading to cell death
(Polyak et al. 1997). Although this remains an interesting
hypothesis, the requirement for the PIGs genes for p53-
dependent cell death has not been established. The num-
ber of different targets related to p53-dependent apopto-
sis may suggest that these diverse genes may be relevant
in different contexts of p53-dependent apoptosis.
Here, by examining two of these proapoptotic genes,
bax and KILLER/DR5, we show that the levels of p53
activation of transcription of these genes does not corre-
late with the fate that cells undergo, as they show simi-
lar levels of accumulation during G1 arrest and apoptosis
in this system. We also attempted to examine PIG3 in
our MEF system, but we were unable to detect its ex-
pression. Previous data have suggested, however, that
PIG genes are induced during both G1 arrest and apop-
tosis in colon cancer cell lines (Polyak et al. 1997). Simi-
lar induction of these known p53 target genes in G1 ar-
rest and apoptosis may be a result of having been iden-
tified in screens in which tumor cell lines lacking p53
and counterparts overexpressing p53 were compared,
without a selection for genes specifically involved in
apoptosis (El-Deiry et al. 1993; Okamoto and Beach
1994; Buckbinder et al. 1995; Polyak et al. 1997).
Various lines of evidence suggest that the PERP gene
isolated here is a bona fide p53 target gene. The expres-
sion profiles of PERP resemble those of other p53 target
genes in their kinetics of induction during DNA-damag-
ing agent treatment and in their p53 dependence. Fur-
thermore, evidence for direct regulation of PERP comes
from analysis of the PERP promoter, which we have
shown contains two putative p53 binding sites and is
functionally responsive to p53. PERP is different, how-
ever, from other p53 target genes in that it is expressed to
significantly higher levels in apoptotic MEFs than in G1-
arresting MEFs. This suggests that there may be addi-
tional regulatory elements in the promoter that dictate
the high level of PERP expression seen during apoptosis.
Defining the cis-acting elements involved in PERP ex-
pression may help identify trans-acting factors that co-
operate with p53 to induce apoptosis.
PERP represents a new member of the PMP-22/gas3
family of tetraspan transmembrane proteins implicated
in cell growth regulation (Naef and Suter 1999). PMP-22/
gas3 is the best characterized of this family, having been
identified in two independent contexts. It was originally
identified as a transcript down-regulated during sciatic
nerve injury and consequent increased Schwann cell pro-
liferation in culture (Spreyer et al. 1991; Welcher et al.
1991) and then as the gas3 gene up-regulated upon serum
starvation of NIH-3T3 cells (Schneider et al. 1988). PMP-
22/gas3 was subsequently found to be a commonly al-
tered gene in human demyelinating hereditary neuropa-
thies including CMT1A, HNPP, and Dejerrine Sottas
syndrome (DSS) (Naef and Suter 1999). Each of these dis-
eases has a somewhat different phenotype, with the ob-
served spectrum and severity of symptoms in these pa-
tients depending on gene dosage (Scherer and Chancer
1995). In addition, the “Trembler” mouse carries point
mutations in PMP-22/gas3 and has a series of symptoms
consistent with the disease in humans (Naef and Suter
1999).
Several lines of evidence have suggested that PMP-22/
gas3 plays dual roles: one as a structural component of
myelin and the other as a cell growth regulator (Naef and
Suter 1999). The original clue to its growth regulatory
function was suggested by the fact that it is induced
selectively during serum starvation in NIH-3T3 cells and
Schwann cells. Subsequently, overexpression of PMP-
22/gas3 was shown to induce G1 arrest in Schwann cells
(Zoidl et al. 1995). Furthermore, overexpression of PMP-
22/gas3 in NIH-3T3 fibroblasts induces cell death,
which is inhibitable by both Bcl-2 and DEVD caspase
inhibitors, indicating that it occurs through apoptosis
(Fabretti et al. 1995; Zoidl et al. 1997; Brancolini et al.
1999). Disease-associated PMP-22/gas3 mutants were
inactive in this apoptosis assay, suggesting that loss of
this function may be relevant to pathogenesis. These
findings are provocative given the ability of PERP to in-
duce cell death and suggest further that PERP may be
functionally similar to PMP-22/gas3.
Activation of PERP, a putative tetraspan transmem-
brane protein at the plasma membrane, suggests a novel
mechanism for p53-induced apoptosis, and various pos-
sibilities could be envisioned to explain how PERP acti-
vates cell death. The previously characterized p53 tar-
gets KILLER/DR5 and Fas are so-called death domain-
containing receptors, which bind to adaptor proteins,
thereby sending signals from the plasma membrane to
directly activate the caspases (El-Deiry 1998). Perhaps
analogously to Killer and Fas, PERP could serve as a cell
death receptor, albeit a different type with four mem-
brane-spanning domains, to receive either autocrine or
paracrine signals. Alternatively, a sequence similarity
between PERP and the calcium channel g-subunit (L.D.
Attardi and T. Jacks, unpubl.) suggests that it could have
channel or pore activity, perhaps allowing some crucial
molecule important for activating apoptosis to pass
through. However it exerts its function, PERP might ul-
timately act by affecting regulators of the apoptotic ma-
chinery, such as Bax or Bcl-2, or by directly activating
apoptotic effectors like caspases. PERP and PMP-22/
gas3, both inducers of cell death, may thus constitute a
family of cell death proteins that act through a novel
mechanism.
The cell death activated by p53 in response to hyper-
proliferation is greatly stimulated by cellular stresses
such as DNA damage and hypoxia (Lowe et al. 1993;
Graeber et al. 1996). Moreover, activation of p53-depen-
dent apoptosis by stress is thought to be a mechanism by
which many chemotherapeutic agents act on human tu-
mors (Lowe 1995). Therefore, understanding the p53-me-
diated apoptosis pathway is crucial not only for under-
standing its mode of tumor suppression but also for de-
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vising new cancer therapies aimed at reconstituting the
apoptosis response in the many tumors that lack p53.
Finally, the map location of PERP is consistent with it
being a tumor suppressor. PERP has been assigned to
human chromosome 6q24, a region implicated in the
development of many kinds of cancer. For example, loss
of heterozygosity within this region is associated with
ovarian, breast, and cervical cancers, as well as mela-
noma (Millikin et al. 1991; Foulkes et al. 1993; Noviello
et al. 1996; Mazurenko et al. 1999). PERP, as an apopto-
sis-specific target gene of p53, might be the target of
mutation in such cancers. Future experimentation will
unravel the role of PERP both in the p53 apoptotic path-
way and in tumor suppression.
Materials and methods
Preparation of G1-arrested RNA populations
Wild-type and p53−/− MEFs were isolated as described previ-
ously (see Attardi et al. 1996). To prepare the G1-arrested RNA
population for the subtractive hybridization, wild-type MEFs
(passage 4) were synchronized by first growing to confluence in
DMEM plus 10% FCS for 3 days and then in DMEM plus 0.1%
FCS for 4 days. To stimulate re-entry into the cell cycle, the
cells were reseeded into DMEM plus 10% FCS at 1.0 × 106 cells
per 10-cm dish. After 6 hr, 0.2 µg/ml doxorubicin (Sigma) was
added to induce G1 arrest. After 12 hr of doxorubicin treatment,
cells were collected by trypsinization and frozen as a pellet for
subsequent RNA preparation. Dishes of both treated and un-
treated wild-type and p53−/− MEFs were collected after 18 hr of
doxorubicin treatment for FACS analysis to verify a p53-depen-
dent G1 arrest, as described previously (Brugarolas et al. 1995).
Preparation of apoptotic RNA populations
To obtain E1A-expressing MEFs, both wild-type and p53−/−
MEFs were retrovirally infected as described (McCurrach et al.
1997). To generate apoptotic E1A–p53+/+ and doxorubicin-
treated E1A–p53−/− cells for RNA preparation, cells were plated
at ~ 2.5 × 106 cells per 10-cm dish. In addition, to measure apop-
tosis concurrently, cells of each genotype were plated into wells
of a 24-well tissue culture dish at 2.5 × 104 per well. All cells
were treated with 0.2 µg/ml doxorubicin. For RNA samples,
cells were collected after 17–18 hr of doxorubicin treatment, a
time at which 23% or 31% of E1A–p53+/+ cells (two indepen-
dent experiments) and 0%–1% of E1A–p53−/− cells had under-
gone apoptosis. Apoptosis levels were measured by collecting
both floating and adherent cells from individual 24 wells and
determining the percentage of dead cells by trypan blue staining
as described (McCurrach et al. 1997). The percentages of apop-
totic cells were independently confirmed by staining the cells
with DAPI and counting the percentages showing typical apop-
totic nuclear morphology (Attardi et al. 1996).
RNA preparation
Total RNA was prepared from MEFs pelleted and frozen in liq-
uid nitrogen using Ultraspec RNA (Biotecx), according to the
manufacturer’s instructions. Poly(A)+ RNA was prepared using
Poly(A)Quik mRNA Isolation Kit (Stratagene), also according to
the manufacturer’s directions.
Subtractive hybridization protocol
The subtractive hybridization protocol was performed using the
PCR-Select cDNA subtraction kit (Clontech), according to the
manufacturer’s instructions. Tester cDNA was prepared from
~ 2 µg of poly(A)+ RNA derived from doxorubicin-treated E1A–
p53+/+ MEFs. Driver cDNA was made from ~ 2 µg each of doxo-
rubicin-treated p53+/+ MEF and doxorubicin-treated E1A–p53−/−
MEF poly(A)+ RNA mixed together. At the end of the protocol,
the PCR products were cloned into the pT7-Blue vector (Nova-
gen). Colonies were subjected to differential screening analysis
(Clontech) to eliminate false positives, as described by the
manufacturer. Positive clones were analyzed further by se-
quencing and Northern blotting.
Northern blot analysis
Northern blotting was performed using standard methods. Pre-
hybridization and hybridization were performed using Ex-
pressHyb hybridization solution (Clontech). Probes were pre-
pared using a Prime-It II Random Primer Labeling Kit (Strata-
gene). To strip blots for reprobing, they were incubated 2 × 15
min in boiling water. cDNAs corresponding to Bax, p21,
GAPDH, KILLER/DR5, mdm-2, cyclin G, and cyclin A2 were
used as probes (Macleod et al. 1995; Hurford et al. 1997; El-Deiry
et al. 1998). EST cDNAs corresponding to IGF–BP3 (IMAGE no.
555520) and PMP-22 (IMAGE no. 1480748) were used as probes.
Time course Northerns
MEFs (1 × 106–3 × 106) of the desired genotype were plated per
10-cm dish for each time point. For the UV assays, apoptosis
was induced by removing the medium from the cells and di-
rectly exposing the cells (without the lid) to 20 J/m2 UV light
using a Stratalinker UV cross-linker (Stratagene). For the TNF-a
assays, cells were treated with 20 ng/ml TNF-a (Boehringer
Mannheim). At the indicated time points, cells were collected
and pellets were frozen for subsequent RNA preparation. At
each time point, cell death was measured by trypan blue exclu-
sion.
Luciferase assays
Luciferase assays were performed using the Dual Luciferase Sys-
tem (Promega). MEFs were plated 12 hr before transfection at
2.5 × 104 cells per well of a 24-well plate. A hundred and seventy
nanograms of the pPERPluc1 reporter or a control vector was
transfected into p53−/− MEFs, wild-type MEFs, or p53−/− MEFs
cotransfected with 170 ng of a human p53 expression vector
(hp53DEGFP; K.Tsai, unpubl.). Transfections were performed
using Fugene 6 (Boehringer Mannheim) according to manufac-
turer’s directions. Twenty microliters of lysate was used per
luciferase assay. The pRLSV40 vector encoding Renilla lucifer-
ase was cotransfected in all conditions at a ratio of 1:50 relative
to the reporter, as a control for transfection efficiency. Back-
ground luminescence readings in nontransfected control cells
were subtracted from all reporter luciferase readings, and data
were then normalized to the Renilla luciferase levels.
The pPERPluc1 reporter was constructed by site-directed mu-
tagenesis of the initial ATG of the PERP coding region (to create
an NcoI site) using the Quick Change Site Directed mutagenesis
kit (Stratagene), followed by joining of the 4-kb PERP promoter
region to the initial ATG of luciferase in the pGL3Basic vector
(Promega). The PG13–Luc and MG15–Luc vectors were gifts of
Wafik El-Deiry.
Cloning PERP full-length cDNA
The full-length PERP cDNA was isolated by 58 and 38 RACE
using the Marathon cDNA Amplification Kit (Clontech). The
PERP, a p53 apoptosis-associated target gene
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sequence was analyzed by MOTIF (http://www.motif.genome.
ad.jp) and Pfam (http://www.sanger.ac.uk/Software/Pfam/).
Topology was examined with the TmPred program (http://www.
ch.embnet.org/software/TMPRED form.html). The similarity
to the calcium channel was noted with the SSEARCH program
(http://genome.eerie.fr/bin/ssearch-guess.cgi). Alignment of
PERP with PMP-22 family members was performed with the
DNAStar program Megalign. The human chromosomal map po-
sition of PERP in the human genome was based on the Sanger
Centre estimate (http://www.sanger.ac.uk/HGP/Chr6).
Mammalian expression studies
The PERP ORF was amplified by PCR using primers containing
Sal1 sites and was cloned into the KA mammalian expression
vector (a pcDNA3 derivative encoding the HA tag; R. Shaw,
pers. comm.). The resulting vector is KA–PERP–HA, encoding a
form of PERP with the HA tag at the carboxyl terminus. pCEP4-
hp53 and CMV–b-galactosidase (for reference, see Attardi et al.
1996) have been described previously, and pcDNA-3hu Bcl-2
was the gift of G. Nunez, University of Michigan, Ann Arbor.
MEFs grown on polylysine-coated glass coverslips were trans-
fected with expression constructs using Fugene 6 as described
above. Transfected cells were immunostained 24–48 hr after
transfection, as described previously (Attardi et al. 1996). To
detect PERP–HA, cells were stained with a monoclonal anti-HA
antibody (1:1000; Boehringer Mannheim). For the staining of the
Golgi apparatus, anti-b-COP (1:100; Affinity Bioreagents, Inc.)
was used. To detect mitochondria, Mito-Tracker (Molecular
Probes) was used according to the manufacturer’s instructions.
To detect p53, human p53 monoclonal antibody 1801 (1:50;
Oncogene Science) was used. To detect b-galactosidase, a rabbit
anti-b-galactosidase antibody was used (1:50, 58–38). FITC-
coupled anti-mouse antibodies and rhodamine-coupled anti-
rabbit antibodies (Cappel, 1:1000) were used to visualize mono-
clonal and polyclonal antibodies, respectively. DAPI (1 µg/ml)
was used to stain nuclei. Cell death was assessed by examining
the morphology of positively staining cells.
Retroviral infections
Wild-type and p53−/− MEFs were infected with wild-type or mu-
tant E2F-1DC (D amino acids 410–437) retroviruses, as described
previously (McCurrach et al. 1997), using pMIG–E2F-1 and
pMIG–E2F-1DC constructs (K. Tsai, unpubl.). Forty-eight hours
after the infections were initiated, MEFs were collected for
RNA preparation as described above.
Acknowledgments
We thank Ken Tsai, Reuben Shaw, Karen Cichowski, Karlyne
Reilly, and Raluca Verona for critical reading of the manuscript.
We thank Dan Chasman for help with sequence analysis pro-
grams and Matt Petitt for assistance with graphics. We are grate-
ful to Melissa Rolls and Jamie White for expertise and reagents
to examine PERP subcellular localization. We thank An-
nemieke deVries for assistance with the UV-induced apoptosis
assays. We appreciate the advice of Andy Samuelson and Mari-
sol Soengas on retroviral infections. We are grateful to Wafik
El-Deiry for the KILLER/DR5 probe and the PG13–Luc and
MG15–Luc plasmids, to Gigi Lozano for the mdm-2 probe, to
Jackie Lees for the cyclin A2 and cyclin G probes, and to Gabriel
Nunez for the Bcl-2 expression plasmid. This work has been
supported by funding from the American Cancer Society, the
Bunting Institute at Radcliffe College, and Merck to L.D.A.
S.W.L. is a Rita Allen Foundation Scholar. T.J. is an Associate
Investigator at the Howard Hughes Medical Institute. This
work has been supported by grant CA13106 to S.W.L., and How-
ard Hughes Medical Institute and NCI funding to T.J.
The publication costs of this article were defrayed in part by
payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 USC section
1734 solely to indicate this fact.
References
Attardi, L.D., S.W. Lowe, J. Brugarolas, and T. Jacks. 1996. Tran-
scriptional activation by p53, but not induction of the p21
gene, is essential for oncogene-mediated apoptosis. EMBO J.
15: 3693–3701.
Attardi, L.D. and T. Jacks. 1999. The role of p53 in tumour
suppression lessons from mouse models. Cell. Mol. Life Sci.
55: 48–63.
Bates, S., A.C. Phillips, P.A. Clark, F. Stott, G. Peters, R.L. Lud-
wig, and K.H. Vousden. 1998. p14ARF links the tumour sup-
pressors RB and p53. Nature 395: 124–125.
Brancolini, C., S. Marzinotto, P. Edomi, E. Agostoni, C. Fioren-
tini, H.W. Muller, and C. Schneider. 1999. Rho-dependent
regulation of cell spreading by the tetraspan membrane pro-
tein Gas 3/PMP22. Mol. Biol. Cell 10: 2441–2459.
Brugarolas, J., C. Chandrasekaran, J.I. Gordon, D. Beach, T.
Jacks, and G.H. Hannon. 1995. Radiation-induced cell cycle
arrest compromised by p21 deficiency. Nature 377: 552–557.
Buckbinder, L., R. Talbott, S. Velasco-Miguel, I. Takenaka, B.
Faha, B.R. Seizinger, and N. Kley. 1995. Induction of the
growth inhibitor IGF-binding protein 3 by p53. Nature
377: 646–649.
Caelles, C., A. Helmberg, and M. Karin. 1994. p53-dependent
apoptosis in the absence of transcriptional activation of p53-
target genes. Nature 370: 220–223.
de Stanchina, E., M.E. McCurrach, F. Zindy, S.Y. Shieh, G. Fer-
beyre, A.V. Samuelson, C. Prives, M.F. Roussel, C.J. Sherr,
and S.W. Lowe. 1998. E1A signaling to p53 involves the
p19ARF tumor suppressor. Genes & Dev. 12: 2434–2442.
Debbas, M. and E. White. 1993. Wild-type p53 mediates apop-
tosis by E1A, which is inhibited by E1B. Genes & Dev.
7: 546–554.
Deng, C., P. Zhang, J.W. Harper, S. Elledge, and P. Leder. 1995.
Mice lacking p21CIP1/WAF1 undergo normal development,
but are defective in G1 checkpoint control. Cell 82: 675–684.
El-Deiry, W.S. 1998. Regulation of p53 downstream genes. Se-
min. Cancer Biol. 8: 345–357.
El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Par-
sons, J.M. Trent, D. Lin, W.E. Mercer, K. Kinzler, and B.
Vogelstein. 1993. WAF1, a potential mediator of p53 tumor
suppression. Cell 75: 817–825.
Fabretti, E., P. Edomi, C. Brancolini, and C. Schneider. 1995.
Apoptotic phenotype induced by overexpression of wild-type
gas3/PMP22: Its relation to the demyelinating peripheral
neuropathy CMT1A. Genes & Dev. 9: 1846–1856.
Fearnhead, H.O., J. Rodriguez, E.E. Govek, W. Guo, R. Kobaya-
shi, G. Hannon, and Y.A. Lazebnik. 1998. Oncogene-depen-
dent apoptosis is mediated by caspase-9. Proc. Natl. Acad.
Sci. 95: 13664–13669.
Foulkes, W.D., J. Ragoussis, G.W. Stamp, G.J. Allan, and J.
Trowsdale. 1993. Frequent loss of heterozygosity on chro-
mosome 6 in human ovarian carcinoma. Br. J. Cancer
67: 551–559.
Giaccia, A.J. and M.B. Kastan. 1999. The complexity of p53
modulation: Emerging patterns from divergent signals.
Attardi et al.
716 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on January 29, 2014 - Published by genesdev.cshlp.orgDownloaded from 
Genes & Dev. 12: 2973–2983.
Graeber, T.G., C. Osmanian, T. Jacks, D.E. Housman, C.J. Koch,
S.W. Lowe, and A.J. Giaccia. 1996. Hypoxia mediated selec-
tion of cells with diminished apoptotic potential in solid
tumors. Nature 379: 88–91.
Haupt, Y., S. Rowan, E. Shaulian, K.H. Vousden, and M. Oren.
1995. Induction of apoptosis in HeLa cells by trans-activa-
tion-deficient p53. Genes & Dev. 9: 2170–2183.
Hermeking, H. and D. Eick. 1994. Mediation of c-myc-induced
apoptosis by p53. Science 265: 2091–2093.
Hurford, R.K., D. Cobrinik, M. Lee, and N. Dyson. 1997. pRB
and p107/p130 are required for the regulated expression of
different sets of E2F responsive genes. Genes & Dev.
11: 1447–1463.
Juin, P., A.O. Hueber, T. Littlewood, and G. Evan. 1999. c-Myc-
induced sensitization to apoptosis is mediated through cy-
tochrome C release. Genes & Dev. 13: 1367–1381.
Kastan, M., Q. Zhan, W.S. El-Deiry, F. Carrier, T. Jacks, W.V.
Walsh, B.S. Plunkett, B. Vogelstein, and A.J. Fornace, Jr.
1992. A mammalian cell cycle checkpoint pathway utilizing
p53 and GADD45 is defective in ataxia-telangiectasia. Cell
71: 587–597.
Knudson, C.M., K.S.K. Tung, W.G. Tourtellotte, G.A.J. Brown,
and S.J. Korsmeyer. 1995. Bax-deficient mice with lymphoid
hyperplasia and male germ cell death. Science 270: 96–99.
Lanni, J.S., S.W. Lowe, E.J. Licitra, J.O. Liu, and T. Jacks. 1997.
p53-independent apoptosis induced by paclitaxel through an
indirect mechanism. Proc. Natl. Acad. Sci. 94: 9679–9683.
Levine, A.J. 1997. p53, the cellular gatekeeper for growth and
division. Cell 88: 323–331.
Lowe, S.W. 1995. Cancer therapy and p53. Curr. Opin. Oncol.
7: 547–553.
Lowe, S.W. and H.E. Ruley. 1993. Stabilization of the p53 tumor
suppressor is induced by adenovirus-5 E1A and accompanies
apoptosis. Genes & Dev. 7: 535–545.
Lowe, S.M., H.E. Ruley, T. Jacks, and D.E. Housman. 1993.
p53-dependent apoptosis modulates the cytotoxicity of anti-
cancer agents. Cell 74: 957–967.
Lowe, S.W., S. Bodis, A. McClatchey, L. Remington, H.E. Ruley,
D.E. Fisher, D.E. Housman, and T. Jacks. 1994. p53 status
and the efficacy of cancer therapy in vivo. Science 266: 807–
810.
Macleod, K., N. Sherry, G. Hannon, D. Beach, T. Tokino, K.
Kinzler, B. Vogelstein, and T. Jacks. 1995. p53-dependent
and independent expression of p21, during cell growth, dif-
ferentiation and DNA damage. Genes & Dev. 9: 935–944.
Malkin, D., F.P. Li, L.C. Strong, J.F.J. Fraumeni, C.E. Nelson,
and D.H. Kim. 1990. Germline p53 mutations in a familial
syndrome of breast cancer, sarcomas, and other neoplasms.
Science 250: 1233–1238.
Mazurenko, N., M. Attaleb, T. Gritsko, L. Semjonova, L. Pav-
lova, O. Sakharova, and F. Kisseljov. 1999. High resolution
mapping of chromosome 6 deletions in cervical cancer. On-
col. Rep. 6: 859–863.
McCurrach, M.E., T.M.F. Connor, C.M. Knudson, S.J. Kors-
meyer, and S.W. Lowe. 1997. Bax-deficiency promotes drug
resistance and oncogenic transformation by attenuating p53-
dependent apoptosis. Proc. Natl. Acad. Sci. 94: 2345–2349.
Millikin, D., E. Meese, B. Vogelstein, C. Witkowski, and J.
Trent. 1991. Loss of heterozygosity for loci on the long arm
of chromosome 6 in human malignant melanoma. Cancer
Res. 51: 5449–5453.
Miyashita, T. and J.C. Reed. 1995. Tumor suppressor p53 is a
direct transcriptional activator of the human bax gene. Cell
80: 293–299.
Murphy, M., A. Hinman, and A.J. Levine. 1996. Wild-type p53
negatively regulates the expression of a microtubule-associ-
ated protein. Genes & Dev. 10: 2971–2980.
Naef, R. and U. Suter. 1999. Many facets of the peripheral my-
elin protein PMP22 in myelination and disease. Micr. Res.
Tech. 41: 359–371.
Noviello, C., F. Coujal, and C. Theillet. 1996. Loss of heterozy-
gosity on the long arm of chromosome 6 in breast cancer:
Possibly four regions of deletion. Clin. Cancer Res. 2: 1601–
1606.
O’Connor, L. and A. Strasser. 1999. Fas, p53, and apoptosis.
Science 284: 1431b (in Technical Comments).
Okamoto, K. and D. Beach. 1994. Cyclin G is a transcriptional
target of the tumor suppressor protein p53. EMBO J.
13: 4816–4823.
Oltvai, Z.N., C.L. Milliman, and S.J. Korsmeyer. 1993. Bcl-2
heterodimerizes in vivo with a conserved homolog, Bax, that
accelerated programmed cell death. Cell 74: 609–619.
Owen-Scaub, L.B., W. Zhang, J.C. Cusack, L.S. Angelo, S.M.
Santee, T. Fujiwara, J.A. Roth, A.B. Deisseroth, W.-W.
Zhang, E. Kruzel, and R. Radinsky. 1995. Wild-type human
p53 and a temperature-sensitive mutant induce Fas/APO-1
expression. Mol. Cell. Biol. 15: 3032–3040.
Polyak, K., Y. Xia, J.L. Zweier, K.W. Kinzler, and B. Vogelstein.
1997. A model for p53-induced apoptosis. Nature 389: 300–
305.
Qin, X.Q., D.M. Livingston, W. Kaelin, Jr., and P.D. Adams.
1994. Deregulated transcription factor E2F-1 expression
leads to S-phase entry and p53-mediated apoptosis. Proc.
Natl. Acad. Sci. 91: 10918–10922.
Ryan, K.M. and K.H. Vousden. 1998. Characterisation of struc-
tural p53 mutants which show selective defects in apoptosis
but not cell cycle arrest. Mol. Cell. Biol. 18: 3692–3698.
Sabbatini, P., J. Lin, A.J. Levine, and E. White. 1995. Essential
role for p53-mediated transcription in E1A-induced apopto-
sis. Genes & Dev. 9: 2184–2192.
Sakamuro, D., P. Sabbatini, E. White, and G.C. Prendergast.
1997. The polyproline region of p53 is required to activate
apoptosis but not growth arrest. Oncogene 15: 887–898.
Scherer, S.S. and P.F. Chancer. 1995. Myelin genes: Getting the
dosage right. Nat. Genet. 11: 226–228.
Schneider, C., R.M. King, and L. Philipson. 1988. Genes specifi-
cally expressed at growth arrest of mammalian cells. Cell
54: 787–793.
Sherr, C.J. 1998. Tumor surveillance via the ARF–p53 pathway.
Genes & Dev. 12: 2984–2991.
Soengas, M., R.M. Alarcon, H. Yoshida, A.J. Giaccia, R. Hakem,
T.W. Mak, and S.W. Lowe. 1999. Apaf-1 and Caspase-9 in
p53-dependent apoptosis and tumor inhibition. Science
284: 156–159.
Spreyer, P., G. Kuhn, C.O. Hanemann, C. Gillen, H. Schaal, R.
Kuhn, G. Lemke, and H.W. Muller. 1991. Axon-regulated
expression of a Schwann cell transcript that is homologous
to a ’growth arrest-specific’ gene. EMBO J. 10: 3661–3668.
Symonds, H., L. Krall, L. Remington, M. Saenz-Robles, S. Lowe,
T. Jacks, and T. Van Dyke. 1994. p53-dependent apoptosis
suppresses tumor growth and progression in vivo. Cell
78: 703–711.
Wagner, A.J., J.M. Kokontis, and N. Hay. 1994. Myc-mediated
apoptosis requires wild-type p53 in a manner independent of
cell cycle arrest and the ability of p53 to induce p21 waf1/
cip1. Genes & Dev. 8: 2817–2830.
Welcher, A.A., U. Suter, M. De Leon, G. Jackson Snipes, and
E.M. Shooter. 1991. A myelin protein is encoded by the ho-
mologue of a growth arrest-specific gene. Proc. Natl. Acad.
Sci. 88: 7195–7199.
Wu, G.S., T.F. Burns, E.R. McDonald III, W. Jiang, R. Meng, I.D.
PERP, a p53 apoptosis-associated target gene
GENES & DEVELOPMENT 717
 Cold Spring Harbor Laboratory Press on January 29, 2014 - Published by genesdev.cshlp.orgDownloaded from 
Krantz, G. Kao, D.D. Gan, J.Y. Zhou, R. Muschel, S.R. Ham-
ilton, N.B. Spinner, S. Markowitz, G. Wu, and W. El-Deiry.
1997. KILLER/DR5 is a DNA damage-inducible p53-regu-
lated death receptor gene. Nat. Genet. 17: 141–143.
Wu, X. and A.J. Levine. 1994. p53 and E2F-1 cooperate to me-
diate apoptosis. Proc. Natl. Acad. Sci. 91: 3802–3806.
Yin, C., C.M. Knudson, S.J. Korsmeyer, and T. Van Dyke. 1997.
Bax suppresses tumorigenesis and stimulates apoptosis in
vivo. Nature 385: 637–640.
Yonish-Rouach, E. 1996. Transcriptional activation plays a role
in the induction of apoptosis by transiently transfected wild-
type p53. Oncogene 12: 2197–2205.
Zindy, F., C.M. Eischen, D.H. Randle, T. Kamijo, J.L. Cleveland,
C.J. Sherr, and M.F. Roussel. 1998. Myc signaling via the
ARF tumor suppressor regulates p53-dependent apoptosis
and immortalization. Genes & Dev. 12: 2424–2433.
Zoidl, G., S. Blass-Kampmann, D. D’Urso, C. Schmalenbach,
and H.W. Muller. 1995. Retroviral-mediated gene transfer of
the peripheral myelin protein PMP-22 in Schwann cells:
Modulation of cell growth. EMBO J. 14: 1122–1128.
Zoidl, G., D. D’Urso, S. Blass-Kampmann, C. Schmalenbach, R.
Kuhn, and H.W. Muller. 1997. Influence of elevated expres-
sion of rat wild-type PMP22 and its mutant PMP22Trembler
on cell growth of NIH3T3 fibroblasts. Cell Tissue Res.
287: 459–470.
Attardi et al.
718 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on January 29, 2014 - Published by genesdev.cshlp.orgDownloaded from 
Erratum
Genes & Development 14: 704–718 (2000)
PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family
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